Over 15 years, 42 children aged 2-14 years were diagnosed as having acquired aplastic anaemia. Adequate clinical details were available for 38 children who were categorised as very severe (n=13), severe (n=16), or nonsevere (n=9) by the modified Camitta criteria.
Aplastic anaemia is a rare but often fatal disorder of haemopoiesis. It is characterised by blood pancytopenia and bone marrow hypoplasia and affected 2-4 per million children under 15 years in one Danish series.' The incidence is higher in the Orient,2 probably reflecting increased exposure to environmental toxins and hepatitis.3 The bone marrow failure may be constitutional or acquired: constitutional causes include Fanconi's anaemia, dyskeratosis congenita, and Shwachman's syndrome. Although drugs, toxins, and viruses have been implicated in the aetiology of acquired aplastic anaemia, over 70% of cases are idiopathic.4 There is conflicting evidence that in some cases acquired aplastic anaemia is an immune mediated disorder,5 6 
Discussion
Acquired aplastic anaemia remains a rare but severe disease in childhood. Most cases are idiopathic-in this series only three of 34 children had a possible causative agent, each being infective-and review of the literature indicates that drug or toxin induced aplasia and paroxysmal nocturnal haemoglobinuria are rare among Western children. A higher incidence of aplastic anaemia due to drug toxicity and hepatitis has been described in the Orient.2 3 The mechanism of bone marrow failure is unclear, although there is conflicting evidence from culture experiments for an immune mediated suppression of haemopoiesis. There have been reports of 40-70% of children8 1o 11 and 50-60% of adults7 showing an improvement after immune suppressive treatment with antilymphocyte globulin, although blood values return to normal in only a minority of cases. In several series up to 50% of adults treated with antilymphocyte globulin have subsequently developed a clonal disorder of haemopoiesis including acute myeloid leukaemia, paroxysmal nocturnal haemoglobinuria, or myelodysplasia. 12 13 This argues for an underlying defect of haemopoiesis in many cases. These complications have not been described in children, however, and it is possible that a different mechanism of bone marrow failure operates in childhood. Despite a male preponderance in the adult series, there was no sex difference in incidence in this study.
In this series 29 of 38 children had severe or very severe aplastic anaemia. An increased severity of aplastic anaemia in childhood has been described,'4 although the small number of paediatric cases precludes definite conclusions on relative severity. Haemorrhage or sepsis at diagnosis is associated with a poor prognosis,'5 and in our report five of six children with bleeding at presentation died.
Allogeneic bone marrow transplantation from an HLA full match family donor is the treatment of choice for severe and very severe aplastic anaemia, and in our series five of seven children are alive in full health; this is consistent with other reports.8 11 16 17 It is important that all families are tissue typed soon after diagnosis, and children with a donor and severe or very severe aplastic anaemia should be treated by early transplantation. Bone marrow transplantation from a matched unrelated donor or a family donor with minor mismatch has been successful in some cases. 18 19 Although three children with a matched unrelated donor in this series died, all were late transplants in pretreated patients with a high risk of treatment failure.20 Our present policy is to initiate a matched unrelated donor search for all severely affected children without a suitable family donor soon after diagnosis as the published results of matched unrelated donor transplants are more promising than the outcome with other second line treatment. Preparative regimens influence survival and there have been poor results in patients treated by schedules including methotrexate. The combination of cyclophosphamide with cyclosporin carries a low risk of graft rejection (17%)2 1 and graft versus host disease, although the incidence of long term sequelae such as infertility and secondary malignancies is unclear.
The survival after treatment with oxymetholone alone was poor, consistent with other series,'5 and no better than that obtained with supportive care. 4 Antilymphocyte globulin was of only limited benefit in this series, with no evidence of a survival advantage compared with androgen treatment. Only five of 18 children showed a complete response and patients with a partial response had a high relapse rate. These data are consistent with the 40-50% five year survival reported for children with severe aplastic anaemia receiving antilymphocyte globulin in four paediatric series.8 1 17 20 Werner et al described a 70% response rate but numbers were small and survival data limited in their series.'0 A higher response and survival rate has been described in predominantly adult patients with non-severe aplastic anaemia,7 and a poor outcome is predicted by young age, female sex, neutrophil count <0 2x 109/l, and bleeding or sepsis at diagnosis. 15 The approach to treatment for a child with non-severe aplastic anaemia and an HLA full match family donor is controversial. It is probably best managed by a trial of antilymphocyte globulin in the first instance and with bone marrow transplantation reserved for children with other, poor prognostic features, or who have less than a complete response to antilymphocyte globulin.
For children who fail first line treatment responses have been described after immune suppression by cyclosporin or high doses of methylprednisolone.22 23 Of these cyclosporin is the more promising with a 30% response rate in patients who relapse after or fail to respond to antilymphocyte globulin, and in our series one child has shown steady improvement without toxicity. Treatment with recombinant granulocyte macrophage colony stimulating factor is effective in raising the neutrophil count in aplastic anaemia, but had no effect in patients with very low neutrophil counts or sepsis at the time of treatment,24 and it is essentially supportive therapy.
Despite advances in treatment the prognosis of aplastic anaemia remains poor in a large proportion of cases. New approaches to treatment are required to reduce the morbidity and mortality associated with this disease.
Autoantibodies in juvenile chronic arthritis Autoantibodies against nuclear and other antigens are found in patients with juvenile chronic arthritis. In diseases such as systemic lupus erythematosus and progressive systemic sclerosis family members frequently also have autoantibodies but this aspect has not been investigated as regards juvenile chronic arthritis until now. Such a study has recently been reported from Australia (Southwood et al, Annals of the Rheumatic Diseases 1990; 49:968-72).
They investigated 23 children with the disease and 66 of their first degree relatives. Antinuclear antibodies were found in 16 patients (70%) and nine relatives (14%). In Australia 3-5% of the general population are thought to have such antibodies. Eighteen out of 20 families had at least one member with autoantibodies in addition to the one with juvenile chronic arthritis. Immunoblotting showed patterns shared between probands and other members in five families.
This study confirms that antinuclear antibodies are common in juvenile chronic arthritis and shows that apparently unaffected family members may also have these antibodies. It seems likely that there is a genetically determined tendency to produce autoantibodies in this as in other autoimmune diseases.
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